EXACT Sciences Corporation

EXAS

NASDAQ. Currency in USD

46.18 +0.63 ( +1.38% )

Real time prices: December 06

Market Cap.
8.21B
Beta (5Y monthly)
1.31
Price/Earnings
-
EPS (TTM)
-4.10
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
2.01M
1y Target Est.
60.65
Day's Range
44.67
-
46.34
52 Week's Range
29.27
-
87.23

Historical Summary

Performance
EPS growth
Share Buybacks

About EXACT Sciences Corporation

Sector
Healthcare
Industry
Diagnostics & Research
Website
https://www.exactsciences.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
172.32M
Employees
6420
Address
5505 Endeavor Lane, Madison, WI, United States, 53719
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Latest news

Exact Sciences (EXAS) Just Reclaimed the 20-Day Moving Average
Exact Sciences (EXAS) Just Reclaimed the 20-Day Moving Average

Good things could be on the horizon when a stock surpasses the 20-day simple moving...
By Zacks Investment Research - 5 days ago

Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 44%: Read This Before Placing a Bet
Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 44%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of...
By Zacks Investment Research - 1 week ago

3 Healthcare Stocks That Could Set You Up For Life
3 Healthcare Stocks That Could Set You Up For Life

All offer products that are invaluable to their respective audiences.
By The Motley Fool - 1 week ago

MacroGenics To Surge 138%? Plus This Analyst Sees $50 For Exact Sciences
MacroGenics To Surge 138%? Plus This Analyst Sees $50 For Exact Sciences

BMO Capital boosted the price target on MacroGenics, Inc. (NASDAQ: MGNX) from $5.7 to $16....
By Benzinga - 3 weeks ago

As Cathie Wood's ARK ETF Surges, These 7 Stocks In The Fund Are Up Over 20% In 5 Days
As Cathie Wood's ARK ETF Surges, These 7 Stocks In The Fund Are Up Over 20% In 5 Days

Cathie Wood, the founder, CEO and CIO of ARK Investment Management, has had a tough...
By Benzinga - 3 weeks ago

Cathie Wood's ARK Innovation ETF Marks Record Surge On Thursday: Here's What She Offloaded Amid Market Rally
Cathie Wood's ARK Innovation ETF Marks Record Surge On Thursday: Here's What She Offloaded Amid Market Rally

Cathie Wood-owned ARK Investment Management’s flagship fund, the ARK Innovation ETF (NYSE: ARKK) closed 14.52%...
By Benzinga - 3 weeks ago

Expert Ratings for Exact Sciences
Expert Ratings for Exact Sciences

Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ:EXAS)...
By Benzinga - 4 weeks ago

Raymond James Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know
Raymond James Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know

Raymond James has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower...
By Benzinga - 4 weeks ago